Company intelligence / Profile preview
Intra-Cellular Therapies
New York, New York, United States of Americaintracellulartherapies.com ↗
- Ownership
- Public · ITCI
- Employees
- ~860
- Development stage
- Commercial
01
Overview
CAPLYTA (lumateperone) is FDA-approved for schizophrenia and depressive episodes associated with bipolar I or II disorder. The company has submitted an sNDA for CAPLYTA as an adjunctive treatment for major depressive disorder, which has been accepted for review by the FDA. Multiple Phase 2 and Phase 3 trials are ongoing for various indications.
- Therapeutic areas
- PsychiatryNeurology
- Modalities
- Small molecule drugs
- Industry
- Biotech
02
Drug pipeline
10 assets9 more assets in the full pipeline.
Beyond the preview
Go deeper on Intra-Cellular Therapies.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Intra-Cellular Therapies.